ClinicalTrials.gg
CompletedNCT03482882Updated Aug 31, 2020Results posted

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

A Phase 2 interventional study of Pimavanserin in Treatment of Depression in Adults With Parkinson's Disease (PD), sponsored by ACADIA Pharmaceuticals Inc.. Completed at 21 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by ACADIA Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,715 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.

Enrollment
2,067th of 3,322
47 · median 72
Started
2018
with 163 others
Phase 2
337 of 3,715
63 open now
Registered
1,977th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 2,067th largest by enrollment of the 3,322 interventional ones that give a count, is one of 164 that started in 2018, is one of 337 in phase 2, and was the 1,977th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

582 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

577 more — sign in →

All 582 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger; 206 take children under 18; 314 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.

03

Conditions studied

  • Treatment of Depression in Adults With Parkinson's Disease (PD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Can understand and provide signed , request for medical records and/or subject privacy form if applicable according to local regulations
  2. Has a clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year, defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features:

    1. rest tremor
    2. rigidity
    3. bradykinesia and/or akinesia
    4. postural and gait abnormalities
  3. Meets clinical criteria for depression with Parkinson's disease as listed in the NINDS/NIMH Guidelines
  4. If currently taking an anti-depressant, is being treated with only one SSRI or SNRI antidepressant at a dose within the US FDA-approved dose range. Subjects who are currently taking a second antidepressant or antidepressant augmentation agent at a sub-therapeutic dose or for an inadequate duration at Screening, and can be discontinued from this agent before the Baseline visit (in the opinion of the Investigator), may be eligible for the study.
  5. Is on a stable dose of anti-Parkinson's medication for 1 month prior to Screening
  6. If the subject is female, she must be of non- or agree to use two methods of clinically acceptable

Exclusion criteria

Exclusion Criteria:

  1. Use of an antipsychotic within 3 weeks or 5 half-lives of Baseline (whichever is longer)
  2. Had a myocardial infarction within the 6 months prior to Screening
  3. Has a known personal or family history or symptoms of long syndrome
  4. Evidence of severe or medically significant hepatic or renal impairment on laboratory tests as assessed by the Investigator or Medical Monitor
  5. Has a history of PD psychosis, schizophrenia, or other psychotic disorder, or bipolar I or II disorder.
  6. Actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)
  7. Is pregnant or breastfeeding
  8. Has previously been treated with pimavanserin or is currently taking pimavanserin
  9. Has a sensitivity to pimavanserin or its
  10. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study

Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Drug - pimavanserin

    Drug: Pimavanserin

Interventions

  • Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score

    The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.

    Time frame: From baseline to Week 8

Secondary outcomes

  1. Change From Baseline (CFB) in HAMD-17 Total Score at Weeks 2, 4, and 6

    The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.

    Time frame: 2, 4, and 6 weeks from baseline

  2. Clinical Global Impression-Improvement (CGI-I)

    The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse)

    Time frame: At Week 8

  3. Change From Baseline (CFB) in Clinical Global Impression-Severity (CGI-S)

    The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill).

    Time frame: From baseline to Week 8

  4. Change From Baseline (CFB) in Scale of Outcomes in PD-Sleep Scale (SCOPA) Nighttime Sleep (NS)Score

    The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems.

    Time frame: From baseline to Week 8

  5. Change From Baseline (CFB) in SCOPA Daytime Sleepiness (DS) Score

    The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems.

    Time frame: From baseline to Week 8

  6. The Number (or Percentage) of Responders

    The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression. Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders.

    Time frame: From baseline to Week 8

  7. Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)

    The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine).

    Time frame: From baseline to Week 8

07

Results

Posted Aug 31, 2020

Participant flow

Participant flow — Overall Study
MilestonePimavanserin
Started47
Completed40
Not completed7
Withdrew: Adverse event3
Withdrew: Lost to follow-up1
Withdrew: Protocol violation2
Withdrew: Not further specified1

Outcome measures

PrimaryChange From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score

The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.

Time frame:
From baseline to Week 8
Reported as:
Mean · score on a scale
Change From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score
score on a scalePimavanserin Full Analysis Set
Baseline HAMD-17 total score19.2 ± 0.46
Week 8 HAMD-17 total score8.1 ± 0.77
Statistical analysis
  • Pimavanserin Full Analysis Set · Mixed-effect model repeated measures · p = <0.0001 · Lsm: -10.8 · 95% CI -12.0 to -9.5
SecondaryChange From Baseline (CFB) in HAMD-17 Total Score at Weeks 2, 4, and 6

The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.

Time frame:
2, 4, and 6 weeks from baseline
Reported as:
Mean · score on a scale
Change From Baseline (CFB) in HAMD-17 Total Score at Weeks 2, 4, and 6
score on a scalePimavanserin Full Analysis Set
Baseline HAMD-17 total score19.2 ± 0.46
Week 2 HAMD-17 total score CFB-7.5 ± 0.89
Week 4 HAMD-17 total score CFB-9.7 ± 0.69
Week 6 HAMD-17 total score CFB-9.6 ± 0.69
SecondaryClinical Global Impression-Improvement (CGI-I)

The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse)

Time frame:
At Week 8
Reported as:
Mean · score on a scale
Clinical Global Impression-Improvement (CGI-I)
score on a scalePimavanserin Full Analysis Set
Clinical Global Impression-Improvement (CGI-I)2.0 ± 0.16
SecondaryChange From Baseline (CFB) in Clinical Global Impression-Severity (CGI-S)

The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill).

Time frame:
From baseline to Week 8
Reported as:
Mean · score on a scale
Change From Baseline (CFB) in Clinical Global Impression-Severity (CGI-S)
score on a scalePimavanserin Full Analysis Set
Baseline CGI-S4.1 ± 0.08
8 Week CGI-S CFB-1.8 ± 0.17
SecondaryChange From Baseline (CFB) in Scale of Outcomes in PD-Sleep Scale (SCOPA) Nighttime Sleep (NS)Score

The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems.

Time frame:
From baseline to Week 8
Reported as:
Mean · score on a scale
Change From Baseline (CFB) in Scale of Outcomes in PD-Sleep Scale (SCOPA) Nighttime Sleep (NS)Score
score on a scalePimavanserin Full Analysis Set
Baseline SCOPA-NS6.1 ± 0.51
Week 8 SCOPA-NS CFB-2.1 ± 0.57
SecondaryChange From Baseline (CFB) in SCOPA Daytime Sleepiness (DS) Score

The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems.

Time frame:
From baseline to Week 8
Reported as:
Mean · score on a scale
Change From Baseline (CFB) in SCOPA Daytime Sleepiness (DS) Score
score on a scalePimavanserin Full Analysis Set
Baseline SCOPA-DS5.2 ± 0.56
8 Week SCOPA-DS CFB-2.2 ± 0.50
SecondaryThe Number (or Percentage) of Responders

The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression. Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders.

Time frame:
From baseline to Week 8
Reported as:
Count of participants · Participants
The Number (or Percentage) of Responders
ParticipantsPimavanserin Full Analysis Set
The Number (or Percentage) of Responders27
SecondaryChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)

The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine).

Time frame:
From baseline to Week 8
Reported as:
Mean · score on a scale
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
score on a scalePimavanserin Full Analysis Set
Baseline EQ-5D-5L index score0.6750 ± 0.02551
8 Week EQ-5D-5L index score CFB0.0712 ± 0.02629
Baseline EQ-5D-5L VAS63.9 ± 2.43
8 Week EQ-5D-5L VAS CFB6.7 ± 2.61

Adverse events

Collected over From the time of informed consent through a safety follow-up visit at Week 10. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pimavanserin0/47 (0%)1/47 (2.1%)21/47 (44.7%)
Most frequent serious events
Most frequent serious events
EventPimavanserin
ColitisGastrointestinal disorders1/47
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPimavanserin
FallInjury, poisoning and procedural complications4/47
NauseaGastrointestinal disorders3/47
DiarrhoeaGastrointestinal disorders2/47
OedemaGeneral disorders2/47
Urinary tract infectionInfections and infestations2/47
Skin abrasionInjury, poisoning and procedural complications2/47
Abdominal painGastrointestinal disorders1/47
ConstipationGastrointestinal disorders1/47
GastritisGastrointestinal disorders1/47
VomitingGastrointestinal disorders1/47

Baseline characteristics

Patients treated with study drug

Age, Continuous
Age, Continuous(years)Pimavanserin Safety Analysis Set
Mean69.6 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)Pimavanserin Safety Analysis Set
Female23
Male24
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pimavanserin Safety Analysis Set
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White43
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Pimavanserin Safety Analysis Set
United States47
Duration of Parkinson's Disease (PD)
Duration of Parkinson's Disease (PD)(years)Pimavanserin Safety Analysis Set
Mean7.8 ± 5.39
08

Study locations

21 sites
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • The Parkinson's and Movement Disorder Institute
    Fountain Valley, California 92708, United States
  • SC3 Research-Reseda
    Pasadena, California 91105, United States
  • The Neurology Group
    Pomona, California 91767, United States
  • SC3 Research-Reseda
    Reseda, California 91335, United States
  • CNS Network
    Torrance, California 90502, United States
  • Associated Neurologists, P.C.
    Danbury, Connecticut 06810, United States
  • Parkinson's Disease and Movement Disorder Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • University of Florida
    Gainesville, Florida 32607, United States
  • Parkinson's Disease Treatment Center of SW Florida
    Port Charlotte, Florida 33980, United States
  • Infinity Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Tallahassee Neurological Clinic, P.A.
    Tallahassee, Florida 32308, United States
  • SRI Biosciences, Clinical Trials and Strategic Development Services
    Plymouth, Michigan 48170, United States
  • Washington University School of medicine
    Saint Louis, Missouri 63110, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • David L. Kreitzman, MD, PC
    Commack, New York 11725, United States
  • Asheville Neurology Specialists, PA
    Asheville, North Carolina 28806, United States
  • Neurology/Neurophysiology
    Johnstown, Pennsylvania 15904, United States
  • Booth Gardner Parkinson's Care Center
    Kirkland, Washington 98034, United States
  • Inland Northwest Research
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • DeKarske D, Alva G, Aldred JL, Coate B, Cantillon M, Jacobi L, Nunez R, Norton JC, Abler V. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. J Parkinsons Dis. 2020;10(4):1751-1761. doi: 10.3233/JPD-202058. PubMed 32804101 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2019, 16 months.

Results were first posted in Aug 2020, 1 year 1 month after primary completion.

Of 53 industry-sponsored phase 2 interventional studies under Depression, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 29. This study's 16 months is close to that.

Counting every sponsor, half of 197 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 29, 2018
StartActual
Mar 9, 2018
Primary completionActual
Jul 9, 2019
CompletionActual
Jul 24, 2019
Results first posted
Aug 31, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03482882
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 9, 2018
Primary completion
Jul 9, 2019
Completion
Jul 24, 2019
Results posted
Aug 31, 2020
Last update
Aug 31, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimavanserin

Start the discussion